NDAINJECTIONINJECTABLE
Approved
Aug 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIPOSYN II 10% is an intravenous lipid emulsion comprising safflower oil and soybean oil, indicated for parenteral nutrition support in patients unable to consume adequate nutrition orally or enterally. It provides essential fatty acids and calories as part of total parenteral nutrition (TPN) therapy.
LOE Approaching
As a 40-year-old legacy product approaching LOE with moderate competitive pressure (30), commercial teams are likely focused on defending market share in institutional/hospital settings rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Positions on LIPOSYN II are primarily institutional/hospital-focused roles with emphasis on customer retention and operational efficiency rather than innovation or market expansion. This product offers stability but limited career growth or skill-building in cutting-edge pharma development.
Account ManagerHospital Sales Representative
Worked on LIPOSYN II 10% at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.